Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol binding.
Abstract
Human lymphocytes are known to posessess a catecholamine-responsive adenylate cyclase
which has typical beta-adrenergic specificity. To identify directly and to quantitate
these beta-adenergic receptors in human lymphocytes, (-) [3H] alprenolol, a potent
beta-adrenergic antagonist, was used to label binding sites in homogenates of human
mononuclear leukocytes. Binding of (-) [3H] alprenolol to these sites demonstrated
the kinetics, affinity, and stereospecificity expected of binding to adenylate cyclase-coupled
beta-adrenergic receptors. Binding was rapid (t1/2 less than 30 s) and rapidly reversible
(t1/2 less than 3 min) at 37 degrees C. Binding was a saturable process with 75 +/-
12 fmol (-) [3H] alprenolol bound/mg protein (mean +/- SEM) at saturation, corresponding
to about 2,000 sites/cell. Half-maximal saturation occurred at 10 nM (-) [3H] alprenolol,
which provides an estimate of the dissociation constant of (-) [3H] alprenolol for
the beta-adrenergic receptor. The beta-adrenergic antagonist, (-) propranolol, potently
competed for the binding sites, causing half-maximal inhibition of binding at 9 nM.
beta-Adrenergic agonists also competed for the binding sites. The order of potency
was (-) isoproterenol greater than (-) epinephrine greater than (-)-norepinephrine
which agreed with the order of potency of these agents in stimulating leukocyte adenylate
cyclase. Dissociation constants computed from binding experiments were virtually identical
to those obtained from adenylate cyclase activation studies. Marked stereospecificity
was observed for both binding and activation of adenylate cyclase. (-)Stereoisomers
of beta-adrenergic agonists and antagonists were 9- to 300-fold more potent than their
corresponding (+) stereoisomers. Structurally related compounds devoid of beta-adrenergic
activity such as dopamine, dihydroxymandelic acid, normetanephrine, pyrocatechol,
and phentolamine did not effectively compete for the binding sites. (-) [3H] alprenolol
binding to human mononuclear leukocyte preparations was almost entirely accounted
for by binding to small lymphocytes, the predominant cell type in the preparations.
No binding was detectable to human erythrocytes. These results demonstrate the feasibility
of using direct binding methods to study beta-adrenergic receptors in a human tissue.
They also provide an experimental approach to the study of states of altered sensitivity
to catecholamines at the receptor level in man.
Type
Journal articleSubject
Adenylyl CyclasesAlprenolol
Binding Sites
Epinephrine
Humans
Isoproterenol
Lymphocytes
Norepinephrine
Propranolol
Receptors, Adrenergic
Permalink
https://hdl.handle.net/10161/5932Published Version (Please cite this version)
10.1172/JCI108254Publication Info
Williams, LT; Snyderman, R; & Lefkowitz, RJ (1976). Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol
binding. J Clin Invest, 57(1). pp. 149-155. 10.1172/JCI108254. Retrieved from https://hdl.handle.net/10161/5932.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Robert J. Lefkowitz
The Chancellor's Distinguished Professor of Medicine
Dr. Lefkowitz’s memoir, A Funny Thing Happened on the Way to Stockholm, recounts his
early career as a cardiologist and his transition to biochemistry, which led to his
Nobel Prize win.
Robert J. Lefkowitz, M.D. is Chancellor’s Distinguished Professor of Medicine and
Professor of Biochemistry and Chemistry at the Duke University Medical Center. He
has bee
Ralph Snyderman
James B. Duke Distinguished Professor of Medicine
Dr. Snyderman served as Chancellor for Health Affairs and Dean of the School of Medicine
at Duke University from 1989 to July 2004. During this time, he oversaw the development
of the Duke University Health System and served as its first president and CEO. Dr.
Snyderman’s current focus is personalized health care and he continues to lead these
efforts nationally from his position as Director of the Duke Center for Personalized
Health Care.
Areas of expertise and nationa
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info